Cognition Therapeutics, Inc. announced that the company has reached target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER (COG1201) study (NCT05225415), which is examining the safety and effectiveness of CT1812 in adults with mild-to-moderate dementia with Lewy bodies (DLB). Top-line results are expected in the second half of 2024 after the last participants have completed six months of treatment. The SHIMMER study will assess safety and changes in cognition and executive function as measured by validated scales including the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research Battery (CDR) tools.

In addition, biomarker evidence of disease modification and target engagement will be analyzed. Once available, the company anticipates reporting topline results in a press release and later presenting them at an appropriate medical meeting.